Highlights from DIA Europe 2025
Author: Univ.-Prof. Dr. Matthias P. Schönermark, Chief Strategy Officer at Kintiga At DIA Europe 2025, held from March 18-20 in […]
Author: Univ.-Prof. Dr. Matthias P. Schönermark, Chief Strategy Officer at Kintiga At DIA Europe 2025, held from March 18-20 in […]
Reforming Drug Price Regulation: A Critical Imperative for Pharmaceutical Companies in Germany Author: Dr. Lara Kleinesudeik, Market Access Manager, Germany
Author: Sebastian Vinzens, Senior Medical Writer, Germany On 11 March 2025, the European Commission (EC) proposed the Critical Medicines Act
Author: Jo Wallis The 2025 World Evidence, Pricing and Access (EPA) Congress in Amsterdam brought together over 1,500 attendees from
Author: Sam Bryant, Regulatory Affairs Manager In 2024, the European Medicine Agency (EMA) granted orphan designation for 141 products in
2025 marks 25 years since the Orphan Medicinal Products Regulation (EC) No 141/2000) was introduced by the EMA, offering Health
Kintiga™ to be officially launched at the World EPA Congress in Amsterdam, 5-6 March 2025 Under the new shared
Since January 2025, new innovative drugs have been subject to the European Health Technology Assessment (EU HTA). Initially, the procedure
– The new name, Kintiga, reflects the company’s bold vision to be the indispensable European strategic partner for health technology
Author: Dr. Matthias Schönermark Insightful discussion with Prof. Dr. Matthias P. Schönermark, and Oznur Seyhun, Partner & Anchorwoman at Market